Öncül O, Top C, Cavuslu S: Correlation of serum leptin levels with insulin sensitivity in patients with chronic hepatitis-C infection (Letter). Diabetes Care 25:937, 2002

The name of the third author of the above-listed letter, Saban Cavuslu, was incorrectly given in the May 2002 issue of Diabetes Care. The correct citation of this letter is shown above.

Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 25:1033–1041, 2002

The legends to Figs. 3 and 4 of the above-listed article were mistakenly switched. The correct figures and legends are shown below.

Figure 3—

HbA1c over 1 year of double-blind treatment with placebo (•) or 120 mg orlistat (•). P = 0.002, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Figure 3—

HbA1c over 1 year of double-blind treatment with placebo (•) or 120 mg orlistat (•). P = 0.002, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Close modal
Figure 4—

Fasting serum glucose levels over time with placebo (•) or 120 mg orlistat (•). P = 0.02, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Figure 4—

Fasting serum glucose levels over time with placebo (•) or 120 mg orlistat (•). P = 0.02, least-squares mean difference from placebo in the change from baseline over 52 weeks.

Close modal